Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Invested Capital (2021 - 2025)

Historic Invested Capital for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Invested Capital rose 2886.58% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 2886.58%. This contributed to the annual value of $1.2 billion for FY2025, which is 2886.58% up from last year.
  • Latest data reveals that Krystal Biotech reported Invested Capital of $1.2 billion as of Q4 2025, which was up 2886.58% from $1.1 billion recorded in Q3 2025.
  • Krystal Biotech's 5-year Invested Capital high stood at $1.2 billion for Q4 2025, and its period low was $408.2 million during Q3 2021.
  • In the last 5 years, Krystal Biotech's Invested Capital had a median value of $704.5 million in 2023 and averaged $727.6 million.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 1201.95% in 2022, then skyrocketed by 6325.52% in 2024.
  • Krystal Biotech's Invested Capital (Quarter) stood at $593.6 million in 2021, then fell by 12.02% to $522.2 million in 2022, then skyrocketed by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then increased by 28.87% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.1 billion for Q3 2025, and $1.0 billion during Q2 2025.